Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Announces Sale of Five MassArray Systems

NEW YORK, July 10 – Sequenom of San Diego said Tuesday it had sold five MassArray systems, bringing the number sold in the second quarter to nine.

The purchasers include BioServe Biotechnologies, Centagenetix, Indiana University School of Medicine, LGC, and an undisclosed party. 

"We continue to experience an increasing demand for our MassArray product line," Toni Schuh, CEO of Sequenom, said in a statement.

"The success of our systems business also affords us the opportunity to expand our efforts to include the systematic identification of disease genes with the most significant impact on human health,” he said.

Sequenom did not say how much the systems sold for, but in the past the company has said that the price of the MassArray is between $400,000 and $1.1 million depending on consumables. 

Schuh said that Sequenom hopes to forge licensing deals and partnerships for a sizable number of the 50 candidate disease genes the company has identified, while keeping some of the more interesting targets for internal development.

In May, Sequenom announced that it would acquire Britain’s Gemini Genomics as part of its hstrategy to become a drug developer.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.